Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Ptc Therapeutics Inc.

Headquarters: South Plainfield, NJ, United States of America
Year Founded: 1998
Status: Public
Industry Sector: HealthTechnology
CEO: Matthew B. Klein, MD
Number Of Employees: 939
Enterprise Value: $2,718,385,783
PE Ratio: -11.52
Exchange/Ticker 1: NASDAQ:PTCT
Exchange/Ticker 2: N/A
Latest Market Cap: $4,298,382,336

BioCentury | Feb 18, 2025
Product Development

Remaking Roche

How the once-dominant cancer company has overhauled its strategy for long-term growth
BioCentury | Jan 18, 2025
Product Development

2025 catalysts: New mechanisms in obesity, neurology, ophthalmology

New Year to put new obesity targets to the test, as all eyes on semaglutide in Alzheimer’s and launches in schizophrenia, AMD
BioCentury | Jan 4, 2025
Market Access

Accelerated approval speed bump will limit access, disincentivize orphan drug development

Penn.-based commercial payer using accelerated approval to justify coverage denials of non-oncology products for 18 months
BioCentury | Dec 30, 2024
Product Development

The uncertainty principle: Hello, 2025

BioCentury’s analysts look back at a year when innovation was hot, but markets were not, and predict what’ll make news in 2025
BioCentury | Dec 11, 2024
Data Byte

November’s FDA approvals include Autolus’ CD19 CAR T 

Plus: BridgeBio’s Attruby approved for ATTR-CM, PTC’s gene therapy for AADC deficiency, and Gilead withdrew Trodelvy for urothelial cancer
BioCentury | Dec 10, 2024
Politics, Policy & Law

Biosecure setback & Novartis’ $1B PTC Deal: a BioCentury podcast

Plus: KCC2 activation nears inflection point
BioCentury | Dec 7, 2024
Data Byte

At $1B, PTC-Novartis deal ties record for cash up front

But partnership lands fourth on overall upfront payment
BioCentury | Dec 3, 2024
Deals

The week in deals: Acadia taps Saniona for GABRA3 modulator, and more

Deals Report: Roche-Poseida, Novartis-PTC and Sarepta-Arrowhead forge large deals, as Idorsia keeps the lights on into 2025
BioCentury | Dec 2, 2024
Deals

PTC adds $1B up front, ‘more muscle’ for Huntington program via Novartis deal

Biotech retains upside in licensing agreement for oral therapy derived from same splicing platform as SMA drug
BioCentury | Nov 15, 2024
Regulation

PTC wins gene therapy approval based on small, open-label trial

Biotech expects to sell voucher after winning gene therapy’s approval for AADC deficiency based on 13-patient study
Items per page:
1 - 10 of 404